MedTrace Logo

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

NCT00088829 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-07-11

Study results available
· View outcomes & findings →

Summary

RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.

PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.

Conditions

Interventions

DRUG

paclitaxel

subjects will receive paclitaxel neoadjuvantly

GENETIC

microarray analysis

subjects will have a biopsy to collect tissue for gene microarray analysis

PROCEDURE

biopsy

All subjects will have a biopsy to collect tissue

PROCEDURE

neoadjuvant therapy

paclitaxel is given neoadjuvantly

DRUG

Paclitaxel

All patients will receive paclitaxel neoadjuvantly

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Georgetown University

    lead OTHER

Principal Investigators

  • Minetta C. Liu, MD · Lombardi Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088829 on ClinicalTrials.gov